Evidence map›Paper›PMID 23603534›Full record

ReviewProgress in retinal and eye research2013

Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.

Uday B Kompella, Aniruddha C Amrite, Rashmi Pacha Ravi, Shelley A Durazo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Progress in retinal and eye research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Application of biomaterials and nanotechnology in corneal tissue engineering.The Journal of international medical research · 2023
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Uday B KompellaNanomedicine and Drug Delivery Laboratory, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. uday.kompella@ucdenver.edu
Aniruddha C Amrite
Rashmi Pacha Ravi
Shelley A Durazo

Funding

Transcleral Therapeutics in Diabetic RetinopathyR01EY018940 · NEI · UNIVERSITY OF COLORADO DENVER · PI KOMPELLA, UDAY B · 2010 to 2014
$2.4M
Influence of eye pigmentation and diabetes on retinal drug deliveryR01EY017533 · NEI · UNIVERSITY OF COLORADO DENVER · PI KOMPELLA, UDAY B · 2009 to 2010
$806k
NEI NIH HHS EY017533NEI NIH HHS EY018940NEI NIH HHS R01 EY017533NEI NIH HHS R01 EY018940
6 · The paper itself

Abstract

Treatment and management of diseases of the posterior segment of the eye such as diabetic retinopathy, retinoblastoma, retinitis pigmentosa, and choroidal neovascularization is a challenging task due to the anatomy and physiology of ocular barriers. For instance, traditional routes of drug delivery for therapeutic treatment are hindered by poor intraocular penetration and/or rapid ocular elimination. One possible approach to improve ocular therapy is to employ nanotechnology. Nanomedicines, products of nanotechnology, having at least one dimension in the nanoscale include nanoparticles, micelles, nanotubes, and dendrimers, with and without targeting ligands. Nanomedicines are making a significant impact in the fields of ocular drug delivery, gene delivery, and imaging, the focus of this review. Key applications of nanotechnology discussed in this review include a) bioadhesive nanomedicines; b) functionalized nanomedicines that enhance target recognition and/or cell entry; c) nanomedicines capable of controlled release of the payload; d) nanomedicines capable of enhancing gene transfection and duration of transfection; f) nanomedicines responsive to stimuli including light, heat, ultrasound, electrical signals, pH, and oxidative stress; g) diversely sized and colored nanoparticles for imaging, and h) nanowires for retinal prostheses. Additionally, nanofabricated delivery systems including implants, films, microparticles, and nanoparticles are described. Although the above nanomedicines may be administered by various routes including topical, intravitreal, intravenous, transscleral, suprachoroidal, and subretinal routes, each nanomedicine should be tailored for the disease, drug, and site of administration. In addition to the nature of materials used in nanomedicine design, depending on the site of nanomedicine administration, clearance and toxicity are expected to differ.

Indexed as

Drug Delivery SystemsGene Transfer TechniquesPosterior Eye SegmentAnimalsEye DiseasesHumansMicro-Electrical-Mechanical SystemsNanomedicineNanoparticlesPharmaceutical PreparationsPharmaceutical PreparationsControlled releaseDrug deliveryGene deliveryImagingNanotechnologyStimuli responsive delivery

Identifiers

PMID23603534
PMCPMC3926814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.